Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes.

Front Endocrinol (Lausanne) · 2025 · PMC12515657 · PMID 41089279

Europe PMC DOI

hedged sentences

0.0012

closest p · 0.0× alpha

0.5031

boldest claim

The sentences

highly significantp=0.0012actually significant

A subgroup analysis, stratified by the control group’s intervention, showed a highly significant difference between subgroups (p=0.0012).

also in 132,142 other papers

did not reach statistical significancep = 0.5031not close (p > 0.1)

Despite the observed differences in subgroup mean effects, the test for subgroup differences did not reach statistical significance (Q = 1.37; d.f. = 2; p = 0.5031), indicating that the effect of Relugolix on EHP-30 pain domain scores does not significantly differ across the 10 mg, 20 mg, and 40 mg dosage subgroups.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.